In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The impact of the use of sacubitril/valsartan on clinical and echocardiographic parameters in heart failure patients

Session Poster Session 2

Speaker Abdallah Almaghraby

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : A Almaghraby (Alexandria,EG), M Abdelnabi (Alexandria,EG), T Kemaloglu Oz (Istanbul,TR), M Elgowelly (Alexandria,EG), Y Saleh (Michigan,US), H Badran (Cairo,EG)

Authors:
A Almaghraby1 , M Abdelnabi2 , T Kemaloglu Oz3 , M Elgowelly1 , Y Saleh4 , H Badran5 , 1Alexandria University - Alexandria - Egypt , 2Medical research institute - Alexandria - Egypt , 3Medipol university - Camlica hospital - Istanbul - Turkey , 4Michigan state university - Michigan - United States of America , 5Ain Shams University - Cairo - Egypt ,

Citation:

Background:
Sacubitril/valsartan is a guideline-recommended alternative drug to Angiotensin-Converting enzyme inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) to reduce morbidity and mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF). Recent guideline update specifically advises switching symptomatic HFrEF patients to sacubitril/valsartan for further reduction of morbidity and mortality.
Purpose:
The aim of the work was to demonstrate the clinical effects of the use of sacubitril/valsartan instead of the conventional ACEIs or ARBs in HFrEF patients.
Methods:
A total number of 23 patients with miscellaneous causes of heart failure (14 patients had ischemic etiology, 8 patients had dilated cardiomyopathy and 1 patient had peripartum cardiomyopathy) presented in the setting of heart failure (NYHA III-IV) with normal creatinine clearance. Through clinical examination and baseline 2D transthoracic echocardiography (TTE) was done with an emphasis on left ventricular ejection fraction (LVEF) and end diastolic volume (EDV). All patients received sacubitril/valsartan instead of ACEs inhibitors or ARBs together with beta-blockers, diuretics and Mineralocorticoid antagonists when indicated. Follow-up after 6 months was done to assess patient clinical status as regards heart failure symptoms and follow up TTE as regards LVEF and EDV.
Results:
The mean age of the patients was 46.89 ± 15.4 years, 14 patients (60.87 %) had a baseline NYHA III while 9 patients (39.13%) had NYHA IV. Mean baseline LVEF and EDV were 27.3% ± 8 and 277.11 ± 57.67 ml respectively. At 6 months follow-up, 21 patients (91.3%) had NYHA I while 2 patients had NYHA II (8.7 %), mean LVEF and EDV were 49.05% ± 10.27 and 202.79 ± 64.86 ml respectively. (P<0.001)
Conclusion:
According to this small case series, the use of sacubitril/valsartan was not only associated with improvement of heart failure symptoms but also it was linked to evident improvement of TTE parameters in the form of improved LVEF and reduced EDV at 6-months follow-up.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are